Your browser doesn't support javascript.
loading
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.
Lenart, Klara; Arcoverde Cerveira, Rodrigo; Hellgren, Fredrika; Ols, Sebastian; Sheward, Daniel J; Kim, Changil; Cagigi, Alberto; Gagne, Matthew; Davis, Brandon; Germosen, Daritza; Roy, Vicky; Alter, Galit; Letscher, Hélène; Van Wassenhove, Jérôme; Gros, Wesley; Gallouët, Anne-Sophie; Le Grand, Roger; Kleanthous, Harry; Guebre-Xabier, Mimi; Murrell, Ben; Patel, Nita; Glenn, Gregory; Smith, Gale; Loré, Karin.
Afiliação
  • Lenart K; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
  • Arcoverde Cerveira R; Karolinska University Hospital, Stockholm, Sweden.
  • Hellgren F; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Ols S; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
  • Sheward DJ; Karolinska University Hospital, Stockholm, Sweden.
  • Kim C; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Cagigi A; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
  • Gagne M; Karolinska University Hospital, Stockholm, Sweden.
  • Davis B; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Germosen D; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
  • Roy V; Karolinska University Hospital, Stockholm, Sweden.
  • Alter G; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Letscher H; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Van Wassenhove J; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Gros W; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
  • Gallouët AS; Karolinska University Hospital, Stockholm, Sweden.
  • Le Grand R; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Kleanthous H; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Guebre-Xabier M; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Murrell B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Patel N; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Glenn G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Smith G; Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
  • Loré K; Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
NPJ Vaccines ; 9(1): 17, 2024 Jan 20.
Article em En | MEDLINE | ID: mdl-38245545
ABSTRACT
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-MTM adjuvanted vaccines predominantly elicits immune events in local tissues with little spillover to the periphery. A third dose of an updated vaccine based on the Gamma (P.1) variant 7 months after two immunizations with licensed NVX-CoV2373 resulted in significant enhancement of anti-spike antibody titers and antibody breadth including neutralization of forward drift Omicron variants. The third immunization expanded the Spike-specific memory B cell pool, induced significant somatic hypermutation, and increased serum antibody avidity, indicating considerable affinity maturation. Seven months after immunization, vaccinated animals controlled infection by either WA-1 or P.1 strain, mediated by rapid anamnestic antibody and T cell responses in the lungs. In conclusion, a third immunization with an adjuvanted, low-dose recombinant protein vaccine significantly improved the quality of B cell responses, enhanced antibody breadth, and provided durable protection against SARS-CoV-2 challenge.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article